利妥昔单抗,来那度胺联合奥布替尼方案治疗老年弥漫大B细胞淋巴瘤的临床观察
Clinical Observation of Rituximab,Lenalidomide Combined with Obutinib in the Treatment of Elderly Patients with Diffuse Large B-cell Lymphoma
郎涛 1李雪国 1王如民 1徐艳芳 1古再丽努尔·吾甫尔1
作者信息
- 1. 新疆维吾尔自治区人民医院血液病科 新疆乌鲁木齐 830001
- 折叠
摘要
目的:探讨利妥昔单抗,来那度胺联合奥布替尼方案治疗老年弥漫大B细胞淋巴瘤的临床效果.方法:选取2020.5-2022.6收治的60例老年弥漫大B细胞淋巴瘤患者,分为对照组、观察组,各30例.对照组接受R-mini-CHOP方案化疗,观察组接受利妥昔单抗,来那度胺联合奥布替尼方案,比较两组相关指标.结果:观察组患者客观缓解率比对照组更高(P＜0.05);观察组治疗后CD3+、CD4+水平比对照组更高,CD8+水平比对照组更低(P＜0.05);观察组治疗期间毒副反应总发生率比对照组低(P＜0.05).两组中位 PFS 分别为 14.9 周(95％CI 12～17)和 5.8 周(95％CI 4～7)(P＜0001),两组中位 OS 分别为 20.1 周(95％CI 16～22)和 7.5 周(95％CI 5～9)(P＜0001).结论:利妥昔单抗、来那度胺联合奥布替尼治疗可减轻老年弥漫大B细胞淋巴瘤患者免疫损伤,存在一定安全性,临床疗效显著.
Abstract
Objective:To investigate the clinical effect of rituximab,lenalidomide combined with aubutinib in the treatment of el-derly patients with diffuse large B-cell lymphoma.Methods:Sixty elderly patients with diffuse large B cell lymphoma admitted to 2020.5-2022.6 were divided into control group and observation group,with 30 patients each.The control group received chemotherapy with R-mini-CHOP regimen,and the observation group received rituximab,lenalidomide combined with obutinib regimen,to compare the relevant indicators between the two groups.Results:Patients in the observation group had higher rates of objective response than the control group(P＜0.05);they had higher CD3+and CD4+levels,and lower CD8+levels than the control group(P＜0.05);the overall inci-dence of toxic effects during treatment was lower than in the control group(P＜0.05).The median PFS was 14.9(95％CI 12-17)and 5.8(95％CI 4-7)(P＜0001),and the median OS was 20.1(95％CI 16-22)and 7.5(95％CI 5-9)(P＜0001).Conclusion:Treatment with ritux-imab and lenalidomide combined with obutinib can reduce the immune damage in elderly patients with diffuse large B cell lymphoma,with a certain safety profile and significant clinical efficacy.
关键词
弥漫大B细胞淋巴瘤/老年/利妥昔单抗/来那度胺/奥布替尼Key words
Diffuse large B-cell lymphoma/Old age/Rituximab/Lenalidomide/Obutinib引用本文复制引用
出版年
2024
NETL
NSTL
万方数据